Loading the section…
The price of Tarsus Pharmaceuticals, Inc. (TARS) on October 9, 2026 is 73.16 USD, +1.30% on the day. Over 52 weeks the stock traded between 53.89 USD and 91.53 USD; the price now sits 51% of the way up that range. Over the past year the price changed by +4.89%. Market capitalization is 3.15 billion USD, rank 24 among 128 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 3 November 2026 · Earnings calendar
Change over the period shown (line colour): +4.01 %
Tarsus Pharmaceuticals, Inc. trades on Nasdaq under the ticker TARS. The company belongs to the Health care sector. The trading history on this page starts on 16 October 2020.
Over the past 52 weeks TARS has traded between 53.89 $ and 91.53 $. As of 9 October 2026 the price stood 51.20 % of the way from the 52-week low to the high.
Over one year TARS shares rose 4.89 %; over six months they rose 0.83 %. Volatility over 90 days is 50.58 %. Dividends are not included: this is price change only, as of 9 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to sales is 5.9, above the sector median of 4.0. Price to book is 9.0, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 72.22 | 73.93 | 71.20 | 73.16 | 481,800 |
| 8 October 2026 | 73.07 | 74.52 | 70.80 | 72.22 | 642,100 |
| 7 October 2026 | 73.58 | 74.68 | 73.30 | 73.61 | 542,300 |
| 6 October 2026 | 74.48 | 75.26 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Tarsus Pharmaceuticals, Inc. (TARS) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 535.1m $, net income was -48.3m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618, US
Tarsus Pharmaceuticals, Inc. reported revenue of 535M $ and a net loss of 48M $ over the last four quarters. Net margin is −9.02 %. Revenue changed by +128.99 % year over year. Earnings per share are −1.11 $. Market capitalisation is 3.1B $.
TARS has a return on equity of −13.83 %, above the sector median of −41.68 %. Return on assets is −8.31 %, above the sector median of −32.11 %. Operating margin is −9.50 %, above the sector median of −26.84 %.
| 428M |
| RVMDRevolution Medicines, Inc. | 189.76 | +0.87 % | 409M |
| HALOHalozyme Therapeutics, Inc. | 110.42 | +0.53 % | 253M |
| BIIBBiogen Inc. | 225.71 | +3.33 % | 227M |
| KODKodiak Sciences Inc | 99.87 | +5.95 % | 219M |
| 72.94 |
| 74.11 |
| 432,400 |
| 5 October 2026 | 73.22 | 75.00 | 72.76 | 74.46 | 939,600 |
| 2 October 2026 | 75.84 | 75.84 | 72.94 | 73.00 | 1M |
| 1 October 2026 | 78.45 | 79.10 | 75.03 | 75.46 | 1M |
| 30 September 2026 | 76.76 | 78.70 | 76.32 | 78.61 | 2M |
| 29 September 2026 | 76.22 | 77.99 | 75.53 | 76.69 | 418,000 |
| 28 September 2026 | 75.83 | 76.82 | 74.66 | 76.81 | 1M |
| 25 September 2026 | 75.78 | 76.17 | 73.85 | 75.69 | 721,400 |
| 24 September 2026 | 75.33 | 77.91 | 74.44 | 75.96 | 598,500 |
| 23 September 2026 | 77.18 | 77.61 | 74.20 | 74.29 | 674,300 |
| 22 September 2026 | 77.61 | 78.59 | 76.01 | 77.08 | 517,000 |
| 21 September 2026 | 78.09 | 78.57 | 76.39 | 77.46 | 487,100 |
| 18 September 2026 | 78.67 | 79.10 | 77.33 | 78.09 | 711,000 |
| 17 September 2026 | 78.55 | 79.78 | 77.29 | 79.03 | 474,900 |
| 16 September 2026 | 78.38 | 79.75 | 77.08 | 77.64 | 658,800 |
| 15 September 2026 | 80.01 | 80.01 | 77.77 | 78.23 | 622,900 |
| 14 September 2026 | 79.69 | 80.24 | 78.40 | 79.95 | 689,700 |